Table 3.
Serum steroid analysis by LC-MS/MS in an idiopathic intracranial hypertension (IIH) cohort receiving either placebo or the 11β-HSD1 inhibitor AZD4017 at baseline and at 12 weeks
| Serum concentrations in nmol/L (Median ± IQR) | ||||||
|---|---|---|---|---|---|---|
| Placebo (n = 11–12) | AZD4017 (n = 16) | |||||
| Baseline | 12 Weeks | Difference | Baseline | 12 Weeks | Difference | |
| Cortisol | 185.3 ± 124.7 | 184.5 ± 105.0 | –0.8, P = .8 | 195.6 ± 119.3 | 158.2 ± 104.1 | –37.4, P = .6 |
| Cortisone | 38.3 ± 12.9 | 36.9 ± 19.4 | –1.4, P = .8 | 43.9 ± 22.8 | 42.6 ± 27.8 | –1.3, P = .1 |
| Cortisol:cortisone ratio | 4.9 ± 1.4 | 4.7 ± 1.1 | –0.2, P = .8 | 4.8 ± 1.8 | 3.4 ± 1.6 | –1.4, P = .01 |
| Cortisol: DHEA ratio | 11.0 ± 12.0 | 9.7 ± 14.0 | –1.3, P = .1 | 13.4 ± 8.0 | 7.0 ± 4.6 | –6.4, P = .01 |
| Testosterone | 0.8 ± 0.9 | 1.0 ± 1.1 | 0.2, P = .4 | 0.4 ± 1.0 | 1.0 ± 1.1 | 0.6, P = .01 |
| A4 | 3.9 ± 3.6 | 4.9 ± 4.6 | 1.0, P = .2 | 3.9 ± 2.9 | 5.0 ± 2.4 | 1.1, P = .1 |
| DHEA | 14.0 ± 15.6 | 17.6 ± 15.6 | 3.6, P = .5 | 15.5 ± 9.7 | 22.7 ± 12.5 | 7.2, P = .08 |
| 11OHA4 | 2.7 ± 2.6 | 3.8 ± 4.2 | 1.1, P = .9 | 2.8 ± 3.0 | 5.7 ± 1.8 | 2.9, P = .01 |
| 11KA4 | 0.9 ± 0.2 | 0.9 ± 0.4 | 0.0, P = .8 | 0.9 ± 0.5 | 1.3 ± 0.4 | 0.4, P = .01 |
Abbreviations: DHEA, dehydroepiandrosterone; A4, androstenedione; 11OHA4, 11β-hydroxyandrostenedione; 11KA4, 11-ketoandrostenedione.